BMO Capital Markets initiated coverage on Avidity Biosciences with a new price target

3/12/25 7:32:18 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BMO Capital Markets initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $72.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RNA

Date	Price Target	Rating	Analyst
6/17/2025	$55.00	Outperform	Wolfe Research
6/11/2025	$65.00	Strong Buy	Raymond James
3/13/2025	$70.00	Buy	Citigroup
3/12/2025	$72.00	Outperform	BMO Capital Markets
3/7/2025	$70.00	Sector Outperform	Scotiabank
12/20/2024	$72.00	Buy	H.C. Wainwright
11/26/2024	$67.00	Outperform	RBC Capital Mkts
9/24/2024	$59.00	Buy	Goldman